Grifols, ES0171996087

Grifols stock: Third-quarter results set for November 10

Published on 10/20/2026 at 16:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Grifols schedules results for November 10, 2026. Grifols stock costs EUR 10.16 on October 20, 2026 at Lang & Schwarz at 4:31 p.m. CEST in trading.

Reporting date November 10, 2026

  • Grifols is estimated to report third-quarter results on November 10, 2026.
  • The Nasdaq-listed ADR traded at USD 7.66 on October 20, 2026 at 10:38 a.m. ET.
  • Grifols stock costs EUR 10.16 at Lang & Schwarz on October 20, 2026 at 4:31 p.m. CEST.
  • The 12-month range was USD 6.96 to USD 9.90 on October 10, 2026.
Isometrische 3D-Illustration zeigt die Wertschöpfungskette von der Plasmaspende bis zum Medikament bei Grifols S.A. ES0171996087, Illustration mit AI erstellt.

Grifols is estimated to report its third-quarter 2026 results on November 10, 2026, giving investors a defined date for the next operating update. MarketBeat lists the announcement date and a November 3 conference call. Grifols was trading at EUR 10.16 at Lang & Schwarz on October 20, 2026 at 4:31 p.m. CEST.

November 10 sets the next checkpoint

The scheduled report matters because the company is coming off a first-half update published on July 28, 2026. Grifols listed its latest investor release as a report covering the six months through June. The November date will therefore be the next opportunity to assess revenue, earnings and cash generation against the first-half baseline.

What does the price position show?

The Nasdaq-listed American depositary receipt was last at USD 7.66 on October 20, 2026 at 10:38 a.m. ET. MarketBeat reported a 12-month range of USD 6.96 to USD 9.90 on October 10, 2026, placing the latest Nasdaq quote USD 0.70 above the low and USD 2.24 below the high.

Valuation leaves the report in focus

MarketBeat put Grifols' market capitalization at USD 5.08 billion and its price-to-earnings ratio at 39.26 on October 10, 2026. The same source reported a consensus rating of Reduce, based on two Hold ratings and one Sell rating, alongside an average price target of USD 10.00. These figures describe the Nasdaq ADR and are separate from the euro quotation at Lang & Schwarz.

Dates and valuation

The next scheduled date is the November 3, 2026 conference call, followed by the estimated November 10, 2026 results announcement. MarketBeat also listed consensus expectations of USD 0.32 adjusted earnings per share and USD 2.21 billion in revenue for the third quarter, both dated for the upcoming report.

Stock remains tied to the next report

For German-market readers, the key near-term marker is the November reporting date rather than a new price signal. The Nasdaq valuation, the wide 12-month range and the pending earnings release give the stock a concrete set of figures to reassess when Grifols publishes its third-quarter update.

The further course of trading is shown by the continuously updated real-time quote of Grifols stock.

Key Grifols figures

  • Company: Grifols, S.A.
  • ISIN: ES0171996087
  • Ticker: GRFS
  • Primary exchange: Nasdaq
  • Price Lang & Schwarz (as of October 20, 2026, 4:31 p.m. CEST): EUR 10.16
  • Sector / Industry: Healthcare / Drug Manufacturers - General
  • Next earnings date: November 10, 2026

Market context: Market report IBEX 35.

More news and analyses on Grifols stock

Disclaimer...
en | ES0171996087 | GRIFOLS | boerse | 70375128 | bgmi